Oncology Institute Inc (TOI): Back in at 1.03 .

Play Episode

7min

Proactive - Interviews for investors

Alpha HPA eyes global demand with stage 2 facility

Alpha HPA Ltd Managing Director Rob Williamson talked with Proactive at the AIM Small and Midcap conference about how the company is redefining aluminum purification through its novel solvent extraction technology. Alpha HPA is producing high-purity aluminum materials for advanced industries such as semiconductors, lithium-ion batteries, direct lithium extraction, and LED technologies. Williamson explained that while solvent extraction has been used in industries like copper and rare earths, Alpha HPA is the first to apply it to aluminum purification, allowing for significantly reduced energy input and improved sustainability. Williamson said, “We can produce our materials at a 70% lower carbon footprint compared to incumbent manufacturers.” This aligns with growing global demand for cleaner technologies and supports the energy transition. The company recently signed a letter of intent with a customer in the semiconductor market, targeting an alloy used in polishing silicon carbide wafers. The product is 50% more efficient than alternatives, and Williamson noted the Stage 2 facility, currently under construction, is expected to have 10,000 tonnes of annual capacity to meet rising demand. With a compelling cost structure and an average sales price of around USD 25 per kilo versus a material input cost of approximately USD 500 per tonne, Alpha HPA believes it is well-positioned for strong margins and market growth. #AlphaHPA #AluminumPurification #Semiconductors #GreenTechnology #EnergyTransition #HighPurityAluminum #CleanTech #BatteryMaterials #SustainableManufacturing #Stage2Facility

Proactive - Interviews for investors

Southern Cross Gold reveals Sunday Creek scale

Southern Cross Gold Consolidated CEO Michael Hudson talked with Proactive at the AIM's Small and Midcap Conference about the company’s focus on gold and antimony exploration in Victoria, Australia, particularly at the Sundae Creek project. Hudson outlined the scale and significance of the discovery, describing it as “one of the most exciting gold discoveries globally… a rare tier one multi-million ounce high grade discovery.” The company is advancing exploration rapidly, with six drill rigs currently operating and plans to expand to eight. Hudson said the company has completed around 70km of drilling and estimates an exploration target of 2.2 to 3.2 million ounces gold equivalent, grading between 8.5 to 10.6 grams per tonne – all within just 5% of the identified trend. Antimony also plays a key role. Hudson explained that China and Russia dominate the global market and recent export bans have highlighted supply vulnerabilities: “You don't have a defense industry without it. And the Western world really doesn't have it. We've got it.” Hudson also reflected on the company’s recent inclusion in the All Ordinaries Index, following the merger of Canadian and Australian entities. He said it marks the first index entry for Southern Cross Gold Consolidated and is “a reflection on a business that's less than three years old.” #SouthernCrossGold #SundayCreek #GoldExploration #Antimony #ASX #MiningStocks #JuniorMiners #ResourceInvesting #MichaelHudson #AllOrdinaries #GoldAndAntimony #AustralianMining

Proactive - Interviews for investors

Qualitas funds soar as banks step back

Qualitas Ltd Group Managing Director Andrew Schwartz talked with Proactive at the AIM's Small and Midcap conference about the company's differentiated position in Australia's real estate investment management landscape. Andrew Schwartz explained that Qualitas operates at scale, supported by large institutional capital. “Some of those investors literally commit amounts of 1.7 billion and above to Qualitas,” he said, noting the firm can fund projects with hundreds of millions—territory once dominated by traditional banks. Schwartz highlighted the company’s deep property expertise, developed over decades, as a key driver of performance. He said, “We are deep sector, deep dive property people,” which allows them to manage funds based not just on lending metrics but also on underlying property fundamentals. The conversation also addressed Qualitas’ notable growth in funds management revenue since its 2021 IPO. Schwartz attributed this to structural shifts in the Australian finance market, where banks still represent 77% of a AU$477 billion sector—but their share is shrinking. “We’ve really got the benefit of filling a void in the market that the bank market just can’t fill,” he said. Roughly 80% of Qualitas' activities are in the housing sector, financing large-scale residential projects rather than retail home loans. Schwartz said the persistent supply shortage, despite rising interest rates, underpins property values and creates strong demand for capital. #Qualitas #RealEstateInvestment #InstitutionalCapital #AustralianHousing #PropertyFinance #AndrewSchwartz #HousingShortage #ASX #FundsManagement #ProactiveInvestors

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Followers	53
Posts	4474
Boards Moderated	0
Alias Born	02/04/2014

Volume:	1,194,005
Day Range:	1.03 - 1.36
Bid:	1.17
Ask:	1.18
Last Trade Time:	11:34:53 AM EDT
Total Trades:	3,061

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

TOI Detailed Quote

Recent TOI News

More TOI News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent TOI News

Go Ad-Free